Navigation Links
MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
Date:5/16/2008

MOUNTAIN VIEW, Calif., May 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008, at 9:00 am (ET) in New York City.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. Transdel Pharmaceuticals Closes $4 Million Financing
3. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
5. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
7. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
8. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
9. Medimetriks Pharmaceuticals, Inc. Begins Operations
10. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
11. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... Parallel6™ ... clinical trials worldwide, announced today that they were named one of the 2017 ... covers the latest developments in the pharmaceutical industry. , “We take pride in honoring ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm ... stem cell technologies for neurodegenerative diseases, announced today that ... Alliance for Regenerative Medicine,s (ARM) 5 th Annual Cell ... at 09:40 EDT in Boston . ... Chief Medical Officer & Chief Operating Officer, will participate in ...
(Date:4/19/2017)... ... , ... A number of new instruments have recently emerged to accommodate different ... Protein and Cell Analysis Education Webinar Series , will focus on advances in the ... future applications. , Many flow cytometers have unique capabilities and the Attune NxT ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark ... Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, ... trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):